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Abstract Two ADP receptors have been identified on
human platelets: P2Y1 and P2Y12. The P2Y12 receptor
blocker clopidogrel is widely used to reduce the risks in
acute coronary syndromes, but, currently, there is no P2Y1
blocker in clinical use. Evidence for variable responses to
clopidogrel has been described in several reports. The
mechanistic explanation for this phenomenon is not fully
understood. The aim of this study was to examine
mechanisms responsible for variability of 2MeS-ADP, a
stable ADP analogue, induced platelet reactivity in clopi-
dogrel-treated patients. Platelet reactivity was assessed by
flow cytometry measurements of P-selectin (CD62P) and
activated GpIIb/IIIa complex (PAC-1). Residual 2MeS-
ADP activation via the P2Y12 and P2Y1 receptors was
determined by co-incubation with the selective antagonists
AR-C69931 and MRS2179 in vitro. P2Y1 and P2Y12
receptor expression on both RNA and protein level were
determined, as well as the P2Y12 H1 or H2 haplotypes. Our
data suggest that the residual platelet activation of 2MeS-
ADP after clopidogrel treatment is partly due to an
inadequate antagonistic effect of clopidogrel on the P2Y12
receptor and partly due to activation of the P2Y1 receptor,
which is unaffected by clopidogrel. Moreover, a correlation
between increased P2Y12 protein expression on platelets
and decreased response to clopidogrel was noticed, r2=0.43
(P<0.05). No correlation was found between P2Y12 mRNA
levels and clopidogrel resistance, indicating post-transcrip-
tional mechanisms. To achieve additional ADP inhibition in
platelets, antagonists directed at the P2Y1 receptor could be
more promising than the development of more potent
P2Y12 receptor antagonists.
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Introduction
ADP receptors play an important role in the activation of
platelets by acting as a positive feedback mechanism. There
is evidence of two different ADP receptors expressed on
human platelets: the Gq-coupled P2Y1 and the Gi-coupled
P2Y12 [1, 2]. The P2Y12 antagonist clopidogrel has been
shown to be an important platelet inhibitor. The Clopidog-
rel versus Aspirin in Patients at Risk of Ischaemic Events
(CAPRIE) and Clopidogrel in Unstable Angina to Prevent
Recurrent Events (CURE) studies demonstrate that inhibi-
tion of the P2Y12 receptor is beneficial, both alone and as a
complement to standard aspirin treatment [3, 4]. At present,
the standard regimen after a non-ST elevation myocardial
infarction or coronary stenting is a combined treatment with
both clopidogrel and aspirin.
However, evidence for a variable response to clopidogrel
has recently been studied [5–7], and clopidogrel resistance
has been associated with an increase in cardiovascular
events [8]. The mechanisms underlying this phenomenon
have not been fully elucidated. An association of clopidog-
rel resistance with the activity of the hepatic cytochrome
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CYP3A4 has been suggested [9]. Medication with atorvas-
tatin has also been proposed to influence the metabolism of
clopidogrel, by acting as a competitive substrate for
CYP3A4 [10]. However, later studies have not been able
to confirm this relationship [11–13]. Other potential
explanations may be variations in receptor expression and
function or variation in intracellular signaling pathways. A
single nucleotide polymorphism (SNP) in the P2Y12
receptor associated with increased function of the receptor
and increased risk for peripheral arterial disease (PAD) has
been described and characterized [14, 15]. Again, a more
recent study has not been able to confirm this association
[16]. It is also plausible that the second ADP receptor
expressed on human platelets, P2Y1, may be involved in
the insufficient inhibition of ADP-mediated platelet activa-
tion after clopidogrel treatment.
We recently developed a real-time quantitative polymer-
ase chain reaction (PCR) method for studies of transcrip-
tional regulation of specific mRNA transcript in human
platelets [1]. It has been useful in clinical studies demon-
strating a down-regulation of P2Y12 receptor mRNA in
patients with systemic lupus erythematosus (SLE) com-
pared with healthy controls [17].
The aim of the present study was to investigate whether
residual 2MeS-ADP, a stable ADP analogue, induced
platelet reactivity after clopidogrel treatment due to
unblocked P2Y1 or to insufficient inhibition of P2Y12
receptor activity. We were also interested in evaluating if
variations in residual platelet reactivity after clopidogrel
treatment could be correlated with receptor properties:




Our study group consisted of 19 patients (six women and
13 men) recently treated by percutaneous coronary inter-
vention (PCI). Blood samples were collected during a visit
to an out patient clinic, at least 2 weeks after the
intervention. All patients were on both aspirin and
clopidogrel and had a median age of 66 years (range 49–
84 years). Eight had a history of previous acute myocardial
infarction, and four had documented diabetes mellitus.
There were 17 on statins and 14 on either angiotensin-
converting enzyme (ACE) inhibitors or angiotensin II
receptor blockers.
The Ethics Committee of Lund University approved the
project. All patients had given written consent prior to
participation in the study.
Blood collection and handling
For flow cytometry, blood was collected in vacutainer
4.5 ml citrate tubes. All experimental procedures were
carried out as fast as possible and always within 10 min of
blood collection. For RNA and protein analysis, blood was
drawn in six vacuette 6 ml EDTA tubes. Platelet rich
plasma (PRP) was then prepared by centrifugation at 160 g
for 20 min at 4°C. PRP was carefully collected without
disturbance of the buffy coat and was centrifuged again at
160 g for 10 min at 4°C to remove contaminating
leukocytes. The PRP was then transferred to a new tube,
and the platelets were collected by centrifugation at 1000 g
for 10 min at 4°C. The platelet pellet was immediately
dissolved in 1 ml TRIzol and frozen at −80°C.
Flow cytometric assessment of platelet activation
Flow cytometric studies were performed on a Becton and
Dickinson FacScan. The following antibodies were used:
fluorescein isothiocyanate (FITC)-conjugated anti-GPIIb/
IIa (PAC-1) antibody, phycoerythrin (PE)-conjugated anti-
P-selectin (CD62P) and peridinin chlorophyll-a protein
(PerCP)-conjugated anti-CD61. 2MeS-ADP (1 μM ) was
used as a stable P2Y agonist. We used the same
concentration, 10 μM, of both antagonists, AR-C 69931
and MRS 2179, based on a dose-finding study made prior
to the clinical study. AR-C 69931 is more potent (IC50
around 0.4 nM) than MRS 2179 (reported IC50 in human
platelets147 nM), but the fact that the P2Y12 receptor in the
clopidogrel-treated patient is already partly blocked
changes this relationship [18, 19]. To achieve roughly the
same amount of inhibition a more potent P2Y12 antagonist
is needed. Five microliters of whole blood was incubated in
phosphate buffered saline (PBS) solution, pH 7.4, contain-
ing agonist, appropriate antagonist and saturating concen-
trations of antibodies in a total volume of 50 μl for 20 min
in the dark at room temperature. The reaction was then
stopped by the addition of 3 ml 1% paraformaldehyde
solution at 4°C followed by 20 min incubation at 4°C in the
dark. Three-color flow cytometry was then performed.
Forward scatter and side scatter were used to gate the
platelet population. A total of 10,000 gated events was
collected. To further exclude other cell types, we included
only CD61 positive cells in the analysis. P-selectin positive
platelets were quantified by determining the percentage of
cells with fluorescence greater than mouse IgG control. For
anti-GPIIb/IIIa antibody, PAC-1, the mean fluorescence
intensities (MFIs) were measured. Inhibition of platelet
activation was expressed as the relative inhibition of
platelet activation after addition of drugs compared with
stimulated platelets.
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RNA and protein extraction
Total cellular RNA and protein was extracted using TRIzol
reagent (Gibco BRL, Life Technology) according to the
supplier’s instructions. The RNA concentration was deter-
mined spectrophotometrically, with a ratio of optical
density (OD) 260:280>1.6 being considered as pure. Samples
were stored at −70°C until required. The quality of RNA
and protein was fully satisfactory in only 14 subjects.
Protein pellets were vacuum dried and dissolved in 1%
sodium dodecyl sulfate solution. DC protein assay (BioRad
Laboratories, USA) was used to determine protein concen-
trations. Protein samples were stored at −20°C until
required.
Quantitative analysis of P2 receptors by real-time reverse
transcription polymerase chain reaction
Total RNAwas reverse-transcribed using Multiscribe RT Kit
(Qiagen, CA, USA) following the manufacturer’s instruc-
tions. Real-time PCR on platelet cDNAwas performed using
the following primers: P2Y12 5′-CTATCGATCGCTACCA
GAAGAC-3′, 5′-TCATGCCAGACTAGACCGAA-3′,
GAPDH 5 ′-GTCCACTGGCGTCTTCACCA-3′, 5 ′-
GTGGCAGTGATGGCATGGAC-3′. Relative gene expres-
sion levels were determined using LightCycler (Roche,
Basle, Switzerland). As a template, 1 μl platelet cDNA was
used in a total volume of 10 μl [3 mM MgCl2, 0.5 μM of
each primer (described below) and 1×LightCycler DNA
Master SYBR Green I mix (Roche)]. The following PCR
amplification protocol was used: initial denaturation at 95°C
for 600 s, followed by 45 PCR cycles at 95°C for 1 s, 55°C
(P2Y12) or 58°C (GAPDH) respectively for 6 s, and 74°C for
23 s. Target gene amplification levels were quantified using a
second-derivative maximum method available in the Light-
Cycler software. P2Y12 receptor expression was determined
using the housekeeping gene GAPDH as a reference. To
validate specificity of amplification reactions, the Light-
Cycler PCR products were sequenced using BigDye v.3.1
(Applied Biosystems, Foster City, CA, USA) according to
the manufacturer’s instructions.
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis
and western blotting
Sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS-PAGE) and western blotting were performed as
described elsewhere [20]. Briefly, 20 μg protein per lane
was separated using 10% SDS-polyacrylamide gels and
transferred onto Immobilon-P membranes (Millipore, Bed-
ford, MA, USA). Sequential detection of P2Y1 and P2Y12
(at 1:200 dilution) and GAPDH (at 1:500 dilution) was
performed according to the following procedure in the
above-mentioned order. Membranes were incubated for 1 h
at room temperature with the appropriate primary antibody,
washed three times with TBS 0.1% Tween, incubated for
1 h with HRP-conjugated secondary antibodies, washed
three times and visualized using the ECL western blotting
system and Hyperfilm. After each round of immunodetec-
tion, the membranes were incubated for 30 min at 50°C in
stripping buffer (100 mM 2-mercapto-ethanol, 2% SDS,
62.5 mM Tris-HCl, pH 6.7) to remove previously bound
antibodies, washed twice in TBS 0.1 % Tween, blocked
with 5% fat-free milk in TBS 0.1% Tween and used again
for the next set of antibodies.
The signal intensity (integral volume) of the appropri-
ately sized bands was scanned and analyzed using Quantity
One software (BioRad). The signal intensities of the
different P2 receptors were normalized to GAPDH to
account for variations in the amounts of total protein
present in each lane.
Determination of P2Y12 haplotype
DNA was isolated from whole blood using the TRIzol
reagent according to the manufacturer’s instructions. A
PCR using HotStarTaq (Qiagen) and the primers 5′-
GAGCACTCAAGACTTTACTGACG-3′ and 5′-GAGAA
GATCAGAAATGACTGTGTTC-3′ was used to amplify
the entire second and parts of the third exon of the of the
P2Y12 gene. The 2233 bp amplification product, containing
two TaiI restriction sites, [at polymorphism i-T744C
(1008 bp from the 5′ end of the amplification product)]
and at a control TaiI site (at 1588 bp), was diluted three
times with water, digested for 1 h with 2U TaiI at 65°C in a
total volume of 30 μl and visualized by agarose gel
electrophoresis. The P2Y12 H1 allele was identified by the
presence of two bands (1588 bp- and 645 bp-long restriction
fragments), and the H2 allele by three bands (1008 bp-,
580 bp- and 465 bp-long restriction fragments) [13].
Reagents, antibodies and drugs
Unless otherwise stated all reagents and drugs were
purchased from Sigma Chemical Corp., St. Louis, MI,
USA. PCR and RT-PCR consumables were purchased from
Perkin-Elmer Applied Biosystems Inc., Foster City, CA,
USA. PCR primers were from MWG Biotech AG, Ebers-
berg, Germany and TRIzol from Invitrogen, Carlsbad, CA,
USA. Western blot reagents were from Amersham Pharma-
cia Biotech, UK, or Bio-Rad Laboratories, USA. Anti-P2Y1
and anti- P2Y12 antibodies were purchased from Alomone
Labs, Israel, and the anti-GAPDH was from Chemicon,
USA. Anti-CD61, anti-CD62P and anti-PAC1 antibodies
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were from BD, USA. MRS 2179 was from Tocris, and
AR-C 69931 was a kind gift from Astra-Zeneca, Sweden. All
drugs were dissolved in 0.9% saline solution.
Statistics and analysis
Calculations and statistics were performed using GraphPad
Prism 4.00 software. Repeated-measures analysis of vari-
ance (ANOVA) with Bonferroni’s post-test was used to
compare flow cytometry data. Values are presented as
mean ± SEM. Comparison of quantitative real-time data
was performed using the method described by Pfaffl [21].
The amplification efficiencies of each primer pair were
tested prior to analysis.
Results
Flow cytometry assessment of platelet activation
After stimulation of platelets with 1 μM 2MeS-ADP,
additional antagonism of the P2Y12 receptor with AR-C
69931 (10 μM), to platelets from patients already treated with
clopidogrel and aspirin, inhibited the residual percentage of P-
selectin positive platelets by 35.8±3.5% (mean ± SEM) (n=19)
and the expression of activated GPIIb/IIIa by 43.5±3.4%. The
blocking of the P2Y1 receptor with MRS 2179 (10 μM)
resulted in a significantly greater inhibition of the percentage
of P-selectin positive platelets by 67.3±4.4% and of activated
GPIIb/IIIa to 54.2±2.6%. Combining the antagonists yielded
an even greater significant inhibition: 78.4±3.8% for P-
selectin and 72.2±2.5% for GPIIb/IIIa. Data are presented in
Figure 1.
Correlation of function with protein and RNA expression
Proteins were run on western blot, and bands from the
P2Y12 receptor and GAPDH were detected. Signal intensi-
ties were quantified, and each P2Y12 reading was normal-
ized to the GAPDH expression in the same sample to
correlate with different loading amounts. The relative
normalized expression of P2Y12 protein correlated with
the percentage of cells expressing P-selectin after stimula-
tion by 2MeS-ADP, with a linear regression of r2=0.43
(P<0.05) (n=14). No correlations were found between
P2Y1 protein levels and P-selectin positive platelets
(r2=0.002, P=0.88, n=14). Data are presented in Figure 2.
Figure 1 Graph showing the increased inhibition of residual ADP-
induced P-selectin positive platelets (a) and expression of activated GPIIb/
IIIa (b) after the further blocking of the P2Y12 receptor with AR-C 69931
(10 μM) and the P2Y1 receptor with MRS 2179 (10 μM) and the
blocking of both receptors with a combination of both antagonists. These
effects are seen in platelets already blocked by clopidogrel and aspirin.
Blocking the P2Y12 receptor further with AR-C 69931 (10 μM)
significantly inhibited the percentage of P-selectin positive platelets by
35.8±3.5% (mean ± SEM) (n=19) and the expression of activated GPIIb/
IIIa by 43.5±3.4%. A significantly greater inhibition was seen when the
P2Y1 antagonist MRS 2179 (10 μM) was used, where the inhibition of P-
selectin increased to 67.3±4.4% and the inhibition of activated GPIIb/IIIa
increased to 54.2±2.6%. Combining the antagonists yielded an even
greater significant inhibition: 78.4±3.8% for P-selectin and 72.2±2.5% for
activated GPIIb/IIIa. There were significance differences between the
groups, P<0.01, in all cases (n=19). Repeated-measures ANOVA with
Bonferroni’s post-test were used to compare data
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P2Y12 and GAPDH mRNA expressions were quantified,
and no correlation was found between the relative expres-
sion levels of the P2Y12 mRNA and the percentage of cells
expressing P-selectin or activated GPIIb/IIIa after stimula-
tion with 2MeS-ADP (r2=0.30, P=0.20 for P-selectin;
r2=0.04, P=0.19 for GPIIb/IIIa) (data not shown).
P2Y12 haplotype and function
The haplotype was determined by PCR sequencing and
restriction digestion. Thirteen patients were homozygous for
the H1 haplotype (H1/H1) and six patients were heterozygous
(H1/H2), whereas none of the patients was homozygous for
the H2 haplotype. There was no difference in the percentage of
platelets expressing P-selectin after 2MeS-ADP (1 μM) in the
homozygous (H1/H1) group compared with the heterozygous
(H1/H2) group (45.2±6.4% for H1/H1 vs 37.0±9.0% for H1/
H2, P=0.47) (unpaired t-test).
Discussion
This study suggests that the residual 2MeS-ADP platelet
reactivity after clopidogrel treatment is in part due to an
inadequate antagonistic effect of clopidogrel on the P2Y12
receptor and partly due to the P2Y1 receptor, which is
unaffected by clopidogrel. Moreover, a correlation between
increased P2Y12 protein expression on platelets and
decreased response to clopidogrel was noticed. No correla-
tion was seen between platelet activation and P2Y12 mRNA
expression or the P2Y12 H1/H2 haplotype.
Our cohort of patients was chosen to reflect the real
clinical situation as much as possible, resulting in a
heterogeneous group having other illnesses and taking
several other medications apart from clopidogrel and aspirin.
The cohort was too small for us to be able to do any
subgroup analyses in terms of other medication, previous
diseases or gender. Since all of the patients were on aspirin,
the impact of reduced prostaglandin synthesis was present
throughout. Despite the inhibition by both clopidogrel and
aspirin, we were able to activate their platelets further with
2MeS-ADP. The remaining 2MeS-ADP activation was
dependent on both insufficient P2Y12 blockade by clopi-
dogrel and the unaffected ADP receptor P2Y1. Most likely,
many different factors contribute to produce the observed
clinical phenotype. One of the most important factors is still
the second ADP receptor, P2Y1, that remains totally
unaffected by clopidogrel. To achieve full ADP inhibition
in the future, increasing the effect of clopidogrel or other
P2Y12 blockers will not suffice. Thus, the clinical benefit of
a P2Y1 blocker will be an interesting alternative.
Despite the use of both AR-C 69931 and MRS 2179,
platelets were not completely inhibited after 2MeS-ADP
stimulation. This was probably due to the very high
concentration of agonist used to stimulate the system;
1 μM of 2MeS-ADP corresponds to a significantly higher
dose of unmodified ADP. The platelet stimulation was also
conducted in whole blood, where leukocytes and erythro-
cytes may also influence the degree of platelet stimulation.
Resistance to the COX-1 inhibitor acetylsalicylic acid
(aspirin) has been studied and debated for many years.
Small observational studies suggest that non-responders to
aspirin are at greater risk of cardiovascular events than are
responders [22–25]. Recently, resistance to clopidogrel has
emerged as an interesting occurrence with a clear clinical
relevance [6–8]. The fact that clopidogrel resistance has an
impact on the cardiovascular outcome in patients with
coronary artery disease merits further studies to elucidate
the underlying mechanisms [8]. Theoretically, many factors
may influence the clopidogrel response: bioavailability,
genetic or transcriptional variations in the metabolizing
enzymes or in the target receptor and interactions with other
Figure 2 The relative expression and GAPDH-normalized expression
of P2Y12 (a) and P2Y1 (b) protein correlated with the percentage of P-
selectin positive platelets after stimulation with 1 μM of 2MeS-ADP.
In (a) there is a significant correlation of P-selectin positive platelets
with P2Y12 protein expression, with r
2=0.43 (P<0.05) (n=14). In (b)
there is no significant correlation of P-selectin positive platelets and
P2Y1 protein expression (r
2=0.002, P=0.88, n=14) (pos plts positive
platelets)
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compounds. One early study demonstrated a correlation
between clopidogrel resistance and atorvastatin medication,
but this hypothesis was later dismissed by several other
studies [11–13]. Currently, two studies have investigated
possible mechanisms underlying clopidogrel resistance. One
study was focused on the hepatic metabolism of the drug, and
the other was focused on the bioavailability of clopidogrel [9,
26]. The bioavailability and the hepatic metabolism of the
pro-drug clopidogrel do seem to be important for clopidogrel
resistance [9, 26]. For the first time we find that increased
platelet P2Y12 receptor protein expression is a component of
clopidogrel resistance. Increased abundance of a receptor
protein may thereby result in less inhibition by its antagonist.
However, whether these patients are constituent high P2Y12
expressers that increase their risk of myocardial infarction is
not known. Animal studies have shown a correlation between
function and overexpression of P2Y1 protein, but we could
not find this association in our clinical material [27].
Platelets are anuclear cells and are therefore unable to
produce new nuclear-derived mRNA transcripts. However,
it has been shown that platelets contain megakaryocyte-
derived mRNA that can be activated upon platelet
stimulation to produce, for example, IL1-β and PAI-1 [28,
29]. Thus, translational regulation can account for the
variation in protein expression. Interestingly, there was no
correlation between P2Y12 mRNA levels and variation of
clopidogrel inhibition. These results suggest that post-
transcriptional regulation of the P2Y12 receptor expression
is responsible for the correlation between P2Y12 protein
expression and the clopidogrel effect. Also, mRNA concen-
trations in platelets are low, and any mRNA correlation that
might have existed in the megakaryocyte may have been lost
in circulating platelets.
Haplotype studies have suggested that the P2Y12 H2
haplotype may have a higher mRNA expression than the H1
haplotype, and that this would explain the functional
differences between the different genotypes [14]. In our
small sample group we could not find any such correlation,
and our results are in concordance with a larger P2Y12
haplotype study by Hetherington et al. [16]. It should be
emphasized that our sample is small and it is therefore hard
to draw any reliable conclusions between polymorphisms
and function.
There are several P2Y12 antagonistic compounds in early
and late clinical trials at the moment: prasugrel, cangrelor,
AZD6140. It will be very interesting to see if these will
encounter the same response variation problems as clopi-
dogrel has. It might also be that different drugs will be better
suited for different clinical phenotypes. With many different
P2Y12 antagonists available in the clinic, a simple clinical
test evaluating patient phenotype would be useful in
choosing the optimal platelet inhibitor. This study also
shows the relevance of designing drugs targeting the P2Y1
receptor.
Conclusion
Variation of clopidogrel inhibition is partly due to the
unblocked P2Y1 receptor and partly due to a variable
antagonistic effect of clopidogrel on the P2Y12 receptor. A
correlation between increased P2Y12 protein expression on
platelets and decreased response to clopidogrel was seen,
indicating a novel explanation to the clopidogrel resistance
phenomenon.
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